Precigen Reports First Quarter 2021 Financial Results
"In the first quarter of 2021, our portfolio, including our most advanced clinical programs, has progressed consistent with guidance," said
Business Highlights:
PRGN-3005 UltraCAR-T®
- Overview: PRGN-3005 UltraCAR-T is a first-in-class investigational therapy under evaluation in a Phase 1/1b clinical trial for the treatment of advanced, recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer. Study subjects receive the PRGN-3005 infusion either via intraperitoneal (IP) (Arm A) or intravenous (IV) (Arm B) infusion (clinical trial identifier: NCT03907527). The study is being conducted in collaboration with the
University of Washington andFred Hutchinson Cancer Research Center . Preliminary Phase 1 data reported from the lowest two dose levels of the IP arm showed a favorable safety profile with no dose-limiting toxicities (DLTs), neurotoxicity or cytokine release syndromes (CRS); encouraging expansion and persistence without lymphodepletion; and clinical activity as evidenced by regression in total target tumor burden. - Enrollment Status: Dose escalation in both IP and IV arms of the Phase 1 trial is ongoing concurrently. Enrollment was completed in dose level 3 of the IP arm and dosing was initiated in dose level 4 of the IP arm. Escalation to higher doses is made possible as a result of the implementation of the UltraPorator™ system for on-site rapid manufacturing. The first patient was dosed in the IV arm after the
US Food and Drug Administration (US FDA ) cleared dosing of patients in the dose escalation phase of the IV arm concurrently with the IP arm. TheUS FDA has cleared enrollment of patients in dose level 3 in the IV arm without the need to follow 3+3 dose escalation through dose levels 1 and 2. - Upcoming Milestones: The Company anticipates the presentation of interim data from the IP arm of the Phase 1 dose escalation trial as well as the initiation of the expansion phase of the IP arm in the second half of 2021.
PRGN-3006 UltraCAR-T®
- Overview: PRGN-3006 UltraCAR-T is a first-in-class investigational therapy currently under evaluation in a Phase 1/1b clinical trial for the treatment of patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes (MDS). Study subjects receive the PRGN-3006 infusion either without prior lymphodepletion (Cohort 1) or following lymphodepleting chemotherapy (Cohort 2) (clinical trial identifier: NCT03927261). The study is being conducted in collaboration with the
H. Lee Moffitt Cancer Center & Research Institute . PRGN-3006 UltraCAR-T has been granted Orphan Drug Designation in patients with AML by theUS FDA . Preliminary Phase 1 data reported for the two lowest dose levels in Cohort 1 and the lowest dose level in Cohort 2 showed a favorable safety profile with no DLTs or neurotoxicity; encouraging expansion and persistence of PRGN-3006 UltraCAR-T in both cohorts; and clinical activity as evidenced by reduction in AML tumor blast levels. One of the patients treated with PRGN-3006 at the lowest dose level with lymphodepletion (Cohort 1), with approximately nine million UltraCAR-T cells, achieved complete remission with incomplete hematologic recovery (CRi) per European Leukemia Net (ELN) criteria. - Enrollment Status: The dose escalation phase of both the lymphodepletion and non-lymphodepletion cohorts of the Phase 1 trial is ongoing concurrently. Enrollment was completed in dose level 3 of the non-lymphodepletion cohort and dose level 2 of the lymphodepletion cohort.
- Upcoming Milestones: The Company anticipates the presentation of interim Phase 1 data as well as the initiation of the dose expansion phase in the second half of 2021.
AG019 ActoBiotics™
- Overview: AG019 ActoBiotics is a first-in-class, orally administered, investigational therapy designed to address the underlying cause of Type 1 diabetes (T1D) and is currently under evaluation in a Phase 1b/2a clinical trial for the treatment of early-onset T1D (clinical trial identifier: NCT03751007; EudraCT 2017-002871-24). Interim data from both the Phase 1b monotherapy and Phase 2a combination arms showed a favorable safety profile with no dose-related adverse events or serious adverse events; an encouraging trend in insulin C-peptide levels, a biomarker for T1D disease progression; an increase in preproinsulin (PPI)-specific Type 1 regulatory (Tr1) cells; and a decrease in PPI specific CD8+ T cells.
- Enrollment Status: Enrollment and dosing is complete in the Phase 1b and Phase 2a portions of the study.
- Clinical Data Presentation at FOCIS 2021: Interim data from the AG019 Phase 1b/2a clinical trial will be presented on
June 10, 2021 at2:05 PM PT as an oral presentation at theFederation of Clinical Immunology Societies (FOCIS) 2021 Virtual Annual Meeting. The abstract entitled, "Lactococcus lactis producing Proinsulin and IL-10 therapy increases Antigen Specific Regulatory T-cells in Monotherapy and in Combination with an anti-CD3 Monoclonal Antibody (Teplizumab) in newly diagnosed T1D patients" will be presented byKevan Herold , MD, CNH Long Professor of Immunobiology and of Medicine (Endocrinology) at theYale School of Medicine .
PRGN-2009 AdenoVerse™ Immunotherapy
- Overview: PRGN-2009 is a first-in-class, off-the-shelf (OTS) investigational immunotherapy utilizing the AdenoVerse platform designed to activate the immune system to recognize and target HPV-positive (HPV+) solid tumors. PRGN-2009 is currently under evaluation in a Phase 1/2 clinical trial as a monotherapy or in combination with bintrafusp alfa (M7824) in patients with HPV-associated cancers (clinical trial identifier: NCT04432597). The study is being conducted under a
Cooperative Research and Development Agreement (CRADA) with theNational Cancer Institute (NCI). Preliminary Phase 1 data from the monotherapy arm of the Phase 1 trial showed that all patients (n=6) received multiple PRGN-2009 administrations and repeated administration of PRGN-2009 treatment was well-tolerated with no DLTs. Preliminary correlative analysis from patients treated with PRGN-2009 monotherapy at dose level 1 (n=3) demonstrated an increase in HPV 16 and/or HPV 18-specific T-cell response post PRGN-2009 administration in 100% (3 of 3) of patients and an increase in the magnitude and breadth of immune response was seen with repeated administrations of PRGN-2009. - Enrollment Status: The Phase 1 monotherapy arm has completed enrollment. Subsequently, the Phase 2 trial in patients with newly diagnosed stage II/III p16-positive oropharyngeal cancer or patients with newly diagnosed operable stage II/III/IVA/IVB HPV+ sinonasal squamous cell cancer was initiated. The first patient in the Phase 2 trial was dosed.
- Preclinical Data Publication: Preclinical data for PRGN-2009 was published in the
Journal of Clinical Investigation entitled, "Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009," which provides the first evaluation of PRGN-2009 and shows promising preclinical antitumor efficacy and induction of HPV-specific T cells, along with the rationale for its evaluation in clinical trials. - Trial-in-Progress Presentation at ASCO 2021: A trial-in-progress update on the PRGN-2009 study will be provided at the
American Society of Clinical Oncology (ASCO) 2021 annual meeting. The abstract entitled, "First-in-human Phase 1/2 trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC)" will be presented as a poster presentation byCharalampos S. Floudas , MD, DMSc, MS, Assistant Research Physician, Genitourinary Malignancies Branch at theCenter for Cancer Research at the NCI. - Upcoming Milestones: The Company anticipates the presentation of interim Phase 1 data in the second half of 2021.
PRGN-2012 AdenoVerse™ Immunotherapy
- Overview: PRGN-2012 is a first-in-class, investigational OTS AdenoVerse immunotherapy designed to elicit immune responses directed against cells infected with HPV 6 or HPV 11 for treatment of recurrent respiratory papillomatosis (RRP). A Phase 1 clinical trial of PRGN-2012 AdenoVerse immunotherapy in adult patients with RRP is ongoing (clinical trial identifier: NCT04724980). In preclinical studies, PRGN-2012 showed robust HPV 6 and HPV 11-specific T-cell responses in RRP patient samples in vitro.
- Orphan Drug Designation: In
March 2021 , the Company received US FDA Orphan Drug Designation for PRGN-2012 AdenoVerse immunotherapy in patients with RRP. - Enrollment Status: In
March 2021 , the first patient was dosed in the Phase 1 study.
First Quarter 2021 Financial Highlights
- Net cash used in operating activities of
$16.4 million in 2021 compared to$27.7 million in 2020; - Cash, cash equivalents, short-term and long-term investments totaled
$209.3 million as ofMarch 31, 2021 ; and - Total revenues of
$24.5 million in 2021 compared to$29.8 million in 2020.
First Quarter 2021 Financial Results Compared to Prior Year Period
Research and development expenses decreased
Total revenues decreased
Trademarks
Cautionary Statement Regarding Forward-Looking Statements
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon Precigen's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of Precigen's business, including the timing, pace and progress of preclinical studies, clinical trials, discovery programs and related milestones, and the promise of the Company's portfolio of therapies, and in particular its CAR-T therapies. Although management believes that the plans, objectives and results reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, and actual future results may be materially different from the plans, objectives and expectations expressed. These risks and uncertainties include, but are not limited to, (i) the impact of the COVID-19 pandemic on our clinical trials, businesses, operating results, cash flows and/or financial condition, (ii)
Investor Contact: Vice President, Investor Relations Tel: +1 (301) 556-9850 |
Media Contact: |
|
|||||||
Consolidated Balance Sheets |
|||||||
(Unaudited) |
|||||||
(Amounts in thousands) |
|
|
|||||
Assets |
|||||||
Current assets |
|||||||
Cash and cash equivalents |
$ |
27,355 |
$ |
51,792 |
|||
Short-term investments |
78,331 |
48,325 |
|||||
Receivables |
|||||||
Trade, net |
20,790 |
16,487 |
|||||
Related parties, net |
12 |
19 |
|||||
Notes |
— |
3,689 |
|||||
Other |
555 |
232 |
|||||
Inventory |
10,637 |
11,359 |
|||||
Prepaid expenses and other |
6,430 |
7,192 |
|||||
Current assets held for sale or abandonment |
8 |
9,853 |
|||||
Total current assets |
144,118 |
148,948 |
|||||
Long-term investments |
103,610 |
— |
|||||
Property, plant and equipment, net |
33,716 |
34,924 |
|||||
Intangible assets, net |
61,230 |
65,396 |
|||||
|
54,238 |
54,363 |
|||||
Right-of-use assets |
8,639 |
9,353 |
|||||
Other assets |
1,433 |
1,603 |
|||||
Total assets |
$ |
406,984 |
$ |
314,587 |
|||
Liabilities and Shareholders' Equity |
|||||||
Current liabilities |
|||||||
Accounts payable |
$ |
4,295 |
$ |
4,598 |
|||
Accrued compensation and benefits |
6,425 |
8,097 |
|||||
Other accrued liabilities |
7,437 |
9,549 |
|||||
Deferred revenue |
3,845 |
2,800 |
|||||
Current portion of long-term debt |
359 |
360 |
|||||
Current portion of lease liabilities |
2,658 |
2,657 |
|||||
Related party payables |
52 |
19 |
|||||
Current liabilities held for sale or abandonment |
172 |
14,047 |
|||||
Total current liabilities |
25,243 |
42,127 |
|||||
Long-term debt, net of current portion |
174,158 |
171,522 |
|||||
Deferred revenue, net of current portion |
23,023 |
23,023 |
|||||
Lease liabilities, net of current portion |
6,943 |
7,744 |
|||||
Deferred tax liabilities |
2,722 |
2,897 |
|||||
Other long-term liabilities |
100 |
100 |
|||||
Total liabilities |
232,189 |
247,413 |
|||||
Commitments and contingencies |
|||||||
Shareholders' equity |
|||||||
Common stock |
— |
— |
|||||
Additional paid-in capital |
2,013,757 |
1,886,567 |
|||||
Accumulated deficit |
(1,840,708) |
(1,823,390) |
|||||
Accumulated other comprehensive income |
1,746 |
3,997 |
|||||
Total shareholders' equity |
174,795 |
67,174 |
|||||
Total liabilities and shareholders' equity |
$ |
406,984 |
$ |
314,587 |
|
|||||||
Consolidated Statements of Operations |
|||||||
(Unaudited) |
|||||||
(Amounts in thousands, except share and per share data) |
Three months ended |
||||||
|
|||||||
2021 |
2020 |
||||||
Revenues |
|||||||
Collaboration and licensing revenues |
$ |
66 |
$ |
10,721 |
|||
Product revenues |
6,381 |
4,961 |
|||||
Service revenues |
17,931 |
13,946 |
|||||
Other revenues |
133 |
210 |
|||||
Total revenues |
24,511 |
29,838 |
|||||
Operating Expenses |
|||||||
Cost of products |
5,574 |
6,089 |
|||||
Cost of services |
7,402 |
7,536 |
|||||
Research and development |
10,521 |
11,327 |
|||||
Selling, general and administrative |
18,702 |
21,486 |
|||||
Total operating expenses |
42,199 |
46,438 |
|||||
Operating loss |
(17,688) |
(16,600) |
|||||
Other Expense, Net |
|||||||
Interest expense |
(4,539) |
(4,592) |
|||||
Interest income |
392 |
673 |
|||||
Other income (expense), net |
(58) |
64 |
|||||
Total other expense, net |
(4,205) |
(3,855) |
|||||
Equity in net loss of affiliates |
(3) |
(351) |
|||||
Loss from continuing operations before income taxes |
(21,896) |
(20,806) |
|||||
Income tax benefit (expense) |
52 |
(40) |
|||||
Loss from continuing operations |
$ |
(21,844) |
$ |
(20,846) |
|||
Income (loss) from discontinued operations, net of income taxes |
4,526 |
(35,152) |
|||||
Net loss |
$ |
(17,318) |
$ |
(55,998) |
|||
Net Loss per Share |
|||||||
Net loss from continuing operations per share, basic and diluted |
$ |
(0.11) |
$ |
(0.13) |
|||
Net income (loss) from discontinued operations per share, basic and diluted |
0.02 |
(0.22) |
|||||
Net loss per share, basic and diluted |
$ |
(0.09) |
$ |
(0.35) |
|||
Weighted average shares outstanding, basic and diluted |
193,499,546 |
160,338,743 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/precigen-reports-first-quarter-2021-financial-results-301287828.html
SOURCE